Novarcel Group
BVI-incorporated investment arm (2018) wholly owned by a family with a biotechnology background, investing across asset classes with a healthcare and biotech emphasis.
USEFUL FOR Fund managers raising capital · Co-investors
Family & background
- HEADQUARTERS
- Hong Kong
- FOUNDED
- 2018
Investment approach
- ROUTES
- Companies (own capital) · Funds (as LP)
- STRATEGIES
- Direct investmentsVenture capitalFunds (as LP)
- LATEST DEAL
- Sirnaomics (Series C2) · Jun 2019
Overview
Novarcel Group Limited was incorporated in the British Virgin Islands in February 2018 and is described in a Sirnaomics HKEX listing document as a professionally managed investment arm wholly owned by a family with two decades in the biotechnology sector. It runs a global multi-asset portfolio with healthcare and biotechnology as one emphasis, reported there at about US$43 million and including Pancea, Illumina Innovation Fund II and 11.2 Capital. It joined Sirnaomics' Series C2 round (June 2019 agreement) and is ultimately beneficially owned by Lili Huang. Its former website no longer resolves.
Holdings & investments (4)
- SirnaomicsBiotech & Life Sciences · since 2019
- Pancea
- Illumina Innovation Fund II
- 11.2 Capital
People
- Lili HuangUltimate beneficial owner · source
Frequently asked questions
Novarcel Group is a single family office based in Hong Kong, founded in 2018.
Novarcel Group invests its own capital into companies and in third-party funds as an LP. Its stated asset mix includes direct investments, venture capital and funds (as lp).
Novarcel Group invests in Biotech & Life Sciences and HealthTech.
Key people at Novarcel Group include Lili Huang (Ultimate beneficial owner).
Novarcel Group's holdings and investments include Sirnaomics, Pancea, Illumina Innovation Fund II and 11.2 Capital.
The most recent publicly reported investment by Novarcel Group is Sirnaomics (Series C2), announced in Jun 2019.